UBS Oncology Impact Fund L.P., 10% Owner at Werewolf Therapeutics, Inc. (HOWL), sold 263,577 shares at $0.99 ($254K) on 2025-11-28, disclosed to the SEC on 2025-12-01.
Scheduled sale ($254k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.98 | 60,733 | $60K | 23.5% |
| 2 | $0.98 | 60,733 | $60K | 23.5% |
| 3 | $0.99 | 20,277 | $20K | 7.9% |
| 4 | $0.94 | 60,917 | $57K | 22.6% |
| 5 | $0.94 | 60,917 | $57K | 22.6% |
| Total | $0.96 avg | 263,577 |
| $254K |
| 100% |
| Filing → |
| ITOS | SELL | 2021-09-27 | $3.2M | — | Filing → |
| CGEM | SELL | 2021-09-02 | $1.3M | — | Filing → |
| HARP | SELL | 2021-05-24 | $541K | — | Filing → |